Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism IL-13 inhibitors(Interleukin-13 inhibitors), IL-4 inhibitors(Interleukin-4 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization MirimGENE Co. Ltd.Startup |
Active Organization MirimGENE Co. Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dermatitis, Atopic | Preclinical | KR | MirimGENE Co. Ltd.Startup | 25 May 2024 |